On April 19, 2022 Eli Lilly and Company (NYSE: LLY) reported its first-quarter 2022 financial results on Thursday, April 28, 2022 (Press release, Eli Lilly, APR 19, 2022, View Source [SID1234612481]). Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at View Source A replay will also be available on the website following the conference call.

On April 19, 2022 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") reported that it has reached a settlement agreement with Hospira, Inc ("Hospira") (Press release, Eagle Pharmaceuticals, APR 19, 2022, View Source [SID1234612480]). Eagle had asserted two Orange Book-listed patents against Hospira related to its new drug application ("NDA") referencing BENDEKA. The settlement agreement provides that Hospira has the right to market its product beginning January 17, 2028, or earlier based on certain circumstances.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased with the outcome of the settlement, as we continue to expand and vigorously defend the intellectual property around BENDEKA and our bendamustine franchise through patent enforcement and litigation," stated Scott Tarriff, President and Chief Executive Officer.

Eagle previously asserted several Orange Book-listed patents against Slayback Pharma LLC, Apotex Inc. ("Apotex") et al, Mylan Laboratories Limited ("Mylan"), and Fresenius Kabi USA, LLC ("Fresenius"), related to their respective abbreviated new drug applications (ANDA’s) referencing BENDEKA. On July 6, 2020, the District Court for the District of Delaware had held these asserted patents both valid and infringed. Apotex, Mylan, and Fresenius appealed this ruling. Prior to the appellate hearing, Eagle settled the litigation with Fresenius, which can market its products beginning in January 2029, or earlier based on certain circumstances. On August 13, 2021, the United States Court of Appeals for the Federal Circuit affirmed that the asserted patents were both valid and infringed. Apotex filed a petition for certiorari on December 14, 2021, which the Supreme Court denied on February 22, 2022. The settlement agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

As previously reported, the U.S. Patent and Trademark Office granted Eagle U.S. Patent No. 11,103,483, entitled "Formulations of Bendamustine," which is listed in the Orange Book and expires in January 2031.

On April 19, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported that it will discuss new data in an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, being held June 11-14, 2022, in Vancouver, British Columbia, Canada (Press release, Cytori Therapeutics, APR 19, 2022, View Source [SID1234612479]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A copy of the presentation titled "Rhenium-186-NanoLiposome (186RNL) in the treatment of relapse/recurrent glioblastoma (rGBM): a novel approach to cancer therapy," will be made available under the Presentations tab of the For Investors section of the Company’s website following the meeting at www.plustherapeutics.com.

On April 19, 2022 Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, and Bull Horn Holdings Corp. (Nasdaq: BHSE) ("Bull Horn"), a special purpose acquisition company (SPAC), reported they have entered into a definitive merger agreement for a business combination that will result in Coeptis becoming a wholly-owned subsidiary of Bull Horn (Press release, Coeptis Pharmaceuticals, APR 19, 2022, View Source [SID1234612478]). Under the terms of the merger agreement, a wholly-owned subsidiary of Bull Horn will merge with and into Coeptis and the holders of the outstanding Coeptis shares will receive equity in Bull Horn valued at $175 million (subject to adjustments). The Boards of Directors of both Coeptis and Bull Horn have unanimously approved the proposed merger, which is subject to customary closing conditions, including receipt of all regulatory approvals, as well as the approval of the proposed merger by Coeptis’ and Bull Horn’s shareholders. The close of the transaction is anticipated to occur in the third quarter 2022, with Bull Horn to domesticate from the British Virgin Islands to a Delaware corporation prior to the closing. Bull Horn will be rebranded and operate as Coeptis Therapeutics Holdings, Inc. and is expected to list on Nasdaq under the ticker symbol "COEP." Coeptis Therapeutics’ current President and Chief Executive Officer, David Mehalick, will lead the combined company as President and Chief Executive Officer, and current Chief Financial Officer of Bull Horn, Chris Calise, will join the post-closing Board of Directors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Coeptis is a developer of cell therapy platforms for cancer with the potential to disrupt conventional treatment paradigms and improve clinical outcomes. Coeptis’ product portfolio is highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is co-developing with VyGen-Bio, Inc. CD38-GEAR-NK is a natural killer (NK) cell-based investigational therapeutic engineered to enable combination therapy with anti-CD38 monoclonal antibodies (mAbs). CD38-Diagnostic is a pre-clinical in vitro screening tool to potentially pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as a monotherapy or in combination with CD38-GEAR-NK.

"Today’s announcement is a key milestone for Coeptis as it gains access to the capital needed to advance our product portfolio highlighted by CD38-GEAR-NK and CD38-Diagnostic," said Mr. Mehalick. "The combination of CD38-GEAR-NK and CD38-Diagnostic has the potential to provide a more targeted administration of anti-CD38 mAbs in the treatment of cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. I would like to thank all those involved in achieving this milestone, including Bull Horn, Bridgeway Capital Partners, our existing and new investors, and the entire Coeptis team."

"We are thrilled to have the opportunity to impact the advancement of technology and assets that will benefit cancer patients through this combination with Coeptis. Led by an exceptional management team, Coeptis is taking a novel approach to treating patients with cancer and expanding its development pipeline," said Mr. Calise. "We are excited by Coeptis’ plans for the technology, and view this opportunity as a significant value driver for our shareholders."

The transaction is subject to closing conditions, including the approval of holders of a majority of the outstanding shares of Coeptis voting stock and Bull Horn ordinary shares, and other customary conditions. Bridgeway Capital Partners and Meister Seelig & Fein LLP served as financial and legal advisors, respectively, to Coeptis. Jones Trading and Ellenoff Grossman & Schole LLP served as financial and legal advisors, respectively, to Bull Horn.

Additional information about the transaction will be provided in a Current Report on Form 8-K to be filed by Bull Horn Holdings Corp. and Coeptis Therapeutics, Inc. with the Securities and Exchange Commission ("SEC") and will be available at the SEC’s website, www.sec.gov.

On April 19, 2022 Today, one year after its founding, Break Through Cancer reported $50 million in grants to support several cutting-edge research projects using a novel "TeamLab" structure—designed to maximize interdisciplinary collaboration among researchers at Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, Koch Institute for Integrative Cancer Research at MIT, and The University of Texas MD Anderson Cancer Center (Press release, Break Through Cancer, APR 19, 2022, View Source;utm_medium=rss&utm_campaign=break-through-cancer-announces-50m-in-grants-to-empower-researchers-from-five-top-cancer-research-centers-to-work-as-one [SID1234612477]). This first-of-its-kind model for collaboration enables researchers to boldly tackle some of the biggest challenges in cancer. Break Through Cancer hopes to overcome conventional barriers to multi-institution teamwork using streamlined systems and advanced analytics for data sharing in real time; umbrella contractual agreements that reduce administrative burdens on researchers; and pioneering policies on intellectual property and authorship.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Foundation is funding four TeamLab-based research projects with an initial investment of more than $50 million in grants to bring new approaches and innovative ideas as rapidly as possible to the clinical challenges of glioblastoma, ovarian, and pancreatic cancers.

"Break Through Cancer and its partner institutions are reducing the siloes in the academic research system as never before," said Tyler Jacks, president, Break Through Cancer. "In just one year’s time, we have built an expansive and impressive community of leading cancer researchers and physicians who can now work as one to accelerate the pace of discovery. This model of radical collaboration will empower many of the brightest minds in cancer research and maximize the capabilities of partner institutions."

Added Jacks, "In the near future, we look forward to partnering with pharmaceutical and biotechnology companies as well as technology developers to further expand the impact of Break Through Cancer."

"To be part of Break Through Cancer’s new model of research collaboration is extremely exciting," said Rebecca Stone, MD, MS, director of the Kelly Gynecologic Oncology Service, associate professor of Gynecology and Obstetrics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and a principal investigator for Break Through Cancer’s funded research in ovarian cancer. "Break Through Cancer has created a fertile ecosystem for nurturing new ideas and rapidly bringing laboratory discovery to advance cancer care."

Break Through Cancer’s initial investment of $50 million will fund the following research projects for an initial three-year period and will include researchers and physicians from all five partner institutions.

Intercepting Ovarian Cancer

Recent research has shown that most, if not all, high grade serous ovarian cancer originates as precursor lesions of the fallopian tubes.
In addition to characterizing precursor lesions located in the fallopian tubes, the team will develop strategies to expand awareness of and access to safe and effective ways for women to undergo fallopian tube removal as a primary prevention strategy, particularly in women who are done having children and are already undergoing elective abdominal surgeries.
Targeting Minimal Residual Disease (MRD) in Ovarian Cancer

A key factor underlying these poor ovarian cancer cure rates is the ability of cancer cells resistant to chemotherapy to persist after frontline treatment.
Among other aims, the research team will develop and benchmark the accuracy of new blood biopsy and "second-look" surgical technologies to monitor MRD at high resolution including extensive use of single-cell analysis.
Revolutionizing GBM Drug Development Through Serial Biopsies

The Revolutionizing GBM (glioblastoma) Drug Development Through Serial Biopsies project will demonstrate the safety and feasibility of carefully performed serial biopsies, and assess how promising new therapies directly affect these brain tumors. The objective of the project is to establish a new paradigm of therapy development for GBM.
The extraordinary level of funding support from Break Through Cancer, highly unusual in GBM research, will be essential to overcoming many financial and logistical barriers to converting the vision of longitudinal tumor sampling into a reality.
Conquering KRAS in Pancreatic Cancer in partnership with the Lustgarten Foundation

The Conquering KRAS in Pancreatic Cancer team will integrate clinical and laboratory approaches to understand why patients do or do not respond to new KRAS directed therapies using powerful technologies to deeply investigate biology in preclinical models and in humans.
The team will develop pharmaceutical partnerships to accelerate the translation of new KRAS inhibitors into effective drugs for this disease.